3,4-dihydroisoquinoline compound and use thereof
Provided in the present invention are a compound as represented by formula (I), or a pharmaceutically acceptable salt, a tautomer, a geometrical isomer, an optical isomer, a solvate or an isotopic derivative thereof, and the use thereof. The compound of the present invention has a significant inhibitory activity on PRMT5, has a significant inhibitory effect on tumor cells and in vivo tumor models, also has a good administration performance, and has clinical application potential for preventing and/or treating diseases which are at least partially mediated by PRMT5.
1 . A compound represented by formula (I), or a pharmaceutically acceptable salt, tautomer, geometric isomer, optical isomer, solvate or isotopic derivative thereof,
wherein
Y is
X is selected from the group consisting of
wherein the N atom linked to R 12 is linked to the pyrimidine ring;
ring A is selected from the group consisting of the following optionally substituted groups: C 3-10 cycloalkyl, 3- to 10-membered heterocycloalkyl, 4- to 12-membered bridged cyclyl, 4- to 12-membered bridged heterocyclyl, monospirocyclyl, monospiroheterocyclyl, fused cyclyl, and fused heterocyclyl, wherein the monospirocyclyl and monospiroheterocyclyl are selected from the group consisting of 3-membered/5-membered, 4-membered/4-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered, and 5-membered/6-membered rings, where the number of ring atoms in each ring includes the number of spiro atom; and wherein the fused cyclyl and fused heterocyclyl are selected from the group consisting of 5-membered/5-membered, 5-membered/6-membered, and 6-membered/6-membered rings, where the number of ring atoms in each ring includes the number of shared atoms;
R 1 , R 2 , R 11 , and R 12 are each independently selected, at each occurrence, from the group consisting of hydrogen and the following optionally substituted groups: C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkyl, C 3-10 cycloalkyl, 3- to 10-membered heterocycloalkyl, C 6-10 aryl, and 5- to 10-membered heteroaryl;
R 3 , R 4 , R 5 , R 6 , and R 7 are each independently selected, at each occurrence, from the group consisting of hydrogen, halogen, hydroxyl, amino, carboxyl, nitro, cyano, oxo, azido, and the following optionally substituted groups: C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkyl, C 1-6 alkoxy, a C 1-6 alkyl ester group, C 1-6 alkylamino, C 1-6 alkylamido, C 3-10 cycloalkyl, 3- to 10-membered heterocycloalkyl, C 3-10 cycloalkylamino, 3- to 10-membered heterocycloalkylamino, C 3-10 cycloalkylamido, 3- to 10-membered heterocycloalkylamido, C 6-10 aryl, and 5- to 10-membered heteroaryl, wherein the oxo denotes that two hydrogen atoms at the same substitution position are substituted with the same oxygen atom to form a double bond; when either of R 4 and R 5 is oxo, the other is absent; when either of R 6 and R 7 is oxo, the other is absent; n is 0, 1, 2, 3, 4, 5 or 6;
R 8 is selected from the group consisting of hydrogen, halogen, cyano, and the following optionally substituted groups: —OR 13 ,—N(R 13 )R 14 ,—NH—C(O)R 13 ,—NH—OR 13 , —OC(O)R 13 ,—C 1-6 alkylene-N(R 13 )R 14 , C 1-6 alkyl, C 3-10 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, 3- to 10-membered heterocycloalkyl, C 6-14 aryl, and 5- to 10-membered heteroaryl, wherein R 13 and R 14 are each independently selected from the group consisting of hydrogen, C 1-6 alkyl, C 3-10 cycloalkyl, 3- to 10-membered heterocycloalkyl, C 6-14 aryl, and 5-to 10-membered heteroaryl;
Q is selected from the group consisting of hydrogen, halogen, cyano, and the following optionally substituted groups: —OR 9 , —N(R 9 )R 10 ,—C(O)R 9 ,—C(O)OR 9 ,—C(O)N(R 9 )R 10 ,—OC(O)R 9 ,—OC(O)N(R 9 )R 10 , C 1-6 alkyl, C 3-10 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, 3- to 10-membered heterocycloalkyl, C 6-14 aryl, 5- to 10-membered heteroaryl, 4- to 12-membered bridged cyclyl, 4- to 12-membered bridged heterocyclyl, monospirocyclyl, monospiroheterocyclyl, fused cyclyl and fused heterocyclyl, wherein R 9 and R 10 are each independently selected from the group consisting of hydrogen, and the following optionally substituted groups: C 1-6 alkyl, C 3-10 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, 3- to 10-membered heterocycloalkyl, C 6-14 aryl, and 5- to 10-membered heteroaryl;
when a group is substituted, a hydrogen atom at a substitutable position of the group is substituted with one or more substituents and the substituents are each independently selected from the group consisting of halogen, hydroxyl, cyano, nitro, amino, azido, oxo, carboxyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 3-10 cycloalkylsulfonyl, 3- to 10-membered heterocycloalkyl, C 6-14 aryl, and 5- to 10-membered heteroaryl, wherein the C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 3-10 cycloalkylsulfonyl, 3- to 10-membered heterocycloalkyl, C 6-14 aryl or 5- to 10-membered heteroaryl is optionally substituted with one or more substituents and the substituents are each independently selected from the group consisting of halogen, hydroxyl, amino, cyano, C 1-6 alkyl, and C 1-6 alkoxy, and oxo denotes that two hydrogen atoms at the same substitution position are substituted with the same oxygen atom to form a double bond; and
when the heterocycloalkyl, bridged heterocyclyl, monospiroheterocyclyl, fused heterocyclyl and/or heteroaryl are present, the number of ring heteroatom in the group is each independently 1 to 4, and the ring heteroatom is each independently selected from the group consisting of N, O, and S.
2 . The compound or the pharmaceutically acceptable salt, tautomer, geometric isomer, optical isomer, solvate or isotopic derivative thereof according to claim 1 , wherein the compound has a structure represented by formula (II):
wherein Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and n are as defined in claim 1 .
3 . The compound or the pharmaceutically acceptable salt, tautomer, geometric isomer, optical isomer, solvate or isotopic derivative thereof according to claim 1 , wherein the compound has a structure represented by formula (III):
wherein X, Q, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and n are as defined in claim 1 .
4 . The compound or the pharmaceutically acceptable salt, tautomer, geometric isomer, optical isomer, solvate or isotopic derivative thereof according to claim 1 ,
wherein ring A is selected from the group consisting of the following optionally substituted groups: C 5-7 cycloalkyl, 4- to 7-membered heterocycloalkyl, 4- to 10-membered bridged cyclyl, 4- to 10-membered bridged heterocyclyl, monospirocyclyl, and monospiroheterocyclyl, wherein the monospirocyclyl and monospiroheterocyclyl are selected from the group consisting of 3-membered/5-membered, 4-membered/4-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered, and 5-membered/6-membered rings, where the number of ring atoms in each ring includes the number of spiro atom; when a group is substituted, a hydrogen atom at a substitutable position of the group is substituted with one or more substituents and the substituents are each independently selected from the group consisting of halogen, hydroxyl, cyano, nitro, amino, azido, oxo, carboxyl, C 1-6 alkyl, and C 1-6 alkoxy, wherein the C 1-6 alkyl or C 1-6 alkoxy is optionally substituted with one or more substituents and the substituents are each independently selected from the group consisting of halogen, hydroxyl, amino, and cyano, and oxo denotes that two hydrogen atoms at the same substitution position are substituted with the same oxygen atom to form a double bond.
5 . The compound or the pharmaceutically acceptable salt, tautomer, geometric isomer, optical isomer, solvate or isotopic derivative thereof according to claim 1 ,
wherein X is
wherein ring A is selected from the group consisting of the following optionally substituted groups: 4- to 6-membered heterocycloalkyl, 4-membered/4-membered monospiroheterocyclyl and 4-membered/6-membered monospiroheterocyclyl, and the atom in ring A that is linked to
is a heteroatom; when a group is substituted, a hydrogen atom at a substitutable position of the group is substituted with one or more substituents and the substituents are each independently selected from the group consisting of halogen, hydroxyl, cyano, amino, C 1-4 alkyl, and C 1-4 alkoxy, wherein the C 1-4 alkyl or C 1-4 alkoxy is optionally substituted with one or more substituents and the substituents are each independently selected from the group consisting of halogen, hydroxyl, amino, and cyano; or
wherein X is
wherein ring A is selected from the group consisting of the following optionally substituted groups: C 5-6 cycloalkyl, 4-membered/4-membered monospirocyclyl, and 4-membered/6-membered monospirocyclyl; when a group is substituted, a hydrogen atom at a substitutable position of the group is substituted with one or more substituents and the substituents are each independently selected from the group consisting of halogen, hydroxyl, cyano, amino, C 1-4 alkyl, and C 1-4 alkoxy, wherein the C 1-4 alkyl or C 1-4 alkoxy is optionally substituted with one or more substituents and the substituents are each independently selected from the group consisting of halogen, hydroxyl, amino, and cyano.
6 . The compound or the pharmaceutically acceptable salt, tautomer, geometric isomer, optical isomer, solvate or isotopic derivative thereof according to claim 1 ,
wherein X is selected from the group consisting of the following optionally substituted fragments:
wherein the N atom at the terminal marked by an asterisk “*” is linked to the pyrimidine ring; and
when a group is substituted, a hydrogen atom at a substitutable position of the group is substituted with one or more substituents and the substituents are each independently selected from the group consisting of halogen, hydroxyl, cyano, amino, C 1-4 alkyl, and C 1-4 alkoxy, wherein the C 1-4 alkyl or C 1-4 alkoxy is optionally substituted with one or more substituents and the substituents are each independently selected from the group consisting of halogen, hydroxyl, amino, and cyano.
7 . The compound or the pharmaceutically acceptable salt, tautomer, geometric isomer, optical isomer, solvate or isotopic derivative thereof according to claim 1 ,
wherein X is selected from the group consisting of the following fragments:
wherein the N atom at the terminal marked by an asterisk “*” is linked to the pyrimidine ring.
8 . The compound or the pharmaceutically acceptable salt, tautomer, geometric isomer, optical isomer, solvate or isotopic derivative thereof according to claim 1 ,
wherein R 8 is selected from the group consisting of hydrogen, and the following optionally substituted groups: —N(R 13 )R 14 ,—C 1-6 alkylene-N(R 13 )R 14 , C 1-6 alkyl, C 3-10 cycloalkyl, and C 6-14 aryl, wherein R 13 and R 14 are each independently selected from the group consisting of hydrogen and C 1-6 alkyl; and
when a group is substituted, a hydrogen atom at a substitutable position of the group is substituted with one or more substituents and the substituents are each independently selected from the group consisting of halogen, hydroxyl, C 3-10 cycloalkyl, C 3-10 cycloalkylsulfonyl, 3- to 10-membered heterocycloalkyl, C 6-14 aryl, and 5- to 10-membered heteroaryl.
9 . The compound or the pharmaceutically acceptable salt, tautomer, geometric isomer, optical isomer, solvate or isotopic derivative thereof according to claim 1 ,
wherein R 8 is selected from the group consisting of —H,
10 . The compound or the pharmaceutically acceptable salt, tautomer, geometric isomer, optical isomer, solvate or isotopic derivative thereof according to claim 1 ,
wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 11 , and R 12 , at each occurrence, are each independently selected from hydrogen.
11 . The compound or the pharmaceutically acceptable salt, tautomer, geometric isomer, optical isomer, solvate or isotopic derivative thereof according to claim 1 ,
wherein Q is —OR 9 , wherein R 9 is selected from the group consisting of hydrogen, and the following optionally substituted groups: C 1-6 alkyl, C 5-7 cycloalkyl, 3- to 10-membered heterocycloalkyl, C 6-14 aryl, and 5- to 10-membered heteroaryl; and
when a group is substituted, a hydrogen atom at a substitutable position of the group is substituted with one or more substituents and the substituents are each independently selected from the group consisting of halogen, hydroxyl, cyano, amino, C 1-4 alkyl, C 1-4 alkoxy, C 3-7 cycloalkyl, and 5- to 7-membered heteroaryl.
12 . The compound or the pharmaceutically acceptable salt, tautomer, geometric isomer, optical isomer, solvate or isotopic derivative thereof according to claim 1 ,
wherein Q is selected from the group consisting of hydroxyl, methoxy, cyclopentyloxy, cyclopropylmethoxy, and pyridin-2-ylmethoxy.
13 . A compound or a pharmaceutically acceptable salt, tautomer, geometric isomer, optical isomer, solvate or isotopic derivative thereof, wherein the compound is one of the following compounds:
14 . A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt, tautomer, geometric isomer, optical isomer, solvate or isotopic derivative thereof according to claim 1 .
15 . A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt, tautomer, geometric isomer, optical isomer, solvate or isotopic derivative thereof according to claim 13 .
16 . A method for treating a disease that is at least partially mediated by PRMT5 or a cell proliferation disease, comprising: administering to a subject in need thereof a therapeutically effective amount of the compound or the pharmaceutically acceptable salt, tautomer, geometric isomer, optical isomer, solvate or isotopic derivative thereof according to claim 1 , wherein the disease that is at least partially mediated by PRMT5 or the cell proliferation disease is a tumor, and the tumor is a hematological tumor or a solid tumor.
17 . A method for treating a disease that is at least partially mediated by PRMT5 or a cell proliferation disease, comprising: administering to a subject in need thereof a therapeutically effective amount of the compound or the pharmaceutically acceptable salt, tautomer, geometric isomer, optical isomer, solvate or isotopic derivative thereof according to claim 16 , wherein the disease that is at least partially mediated by PRMT5 or the cell proliferation disease is a tumor, and the tumor is a hematological tumor or a solid tumor.
18 . The method according to claim 16 , the tumor is selected from the group consisting of lung cancer, bone cancer, stomach cancer, pancreatic cancer, adenoid cystic carcinoma, skin cancer, head and neck cancer, uterine cancer, ovarian cancer, testicular cancer, fallopian tube cancer, endometrial carcinoma, cervical cancer, vaginal cancer, brain cancer, pituitary adenoma, melanoma, acute myeloid leukemia, epidermoid carcinoma, and chronic and acute leukemia.
19 . The method according to claim 17 , the tumor is selected from the group consisting of lung cancer, bone cancer, stomach cancer, pancreatic cancer, adenoid cystic carcinoma, skin cancer, head and neck cancer, uterine cancer, ovarian cancer, testicular cancer, fallopian tube cancer, endometrial carcinoma, cervical cancer, vaginal cancer, brain cancer, pituitary adenoma, melanoma, acute myeloid leukemia, epidermoid carcinoma, and chronic and acute leukemia.
20 . The method according to claim 17 , the tumor is selected from the group consisting of a hematological tumor, stomach cancer, pancreatic cancer, adenoid cystic carcinoma, and melanoma.